메뉴 건너뛰기




Volumn 32, Issue 2, 2015, Pages

Rapid response of brain metastases to alectinib in a patient with non-small-cell lung cancer resistant to crizotinib

Author keywords

Alectinib; Brain metastases; Crizotinib; EML4 ALK; NSCLC

Indexed keywords

ALECTINIB; CRIZOTINIB; ANTINEOPLASTIC AGENT; CARBAZOLE DERIVATIVE; EML4-ALK FUSION PROTEIN, HUMAN; ONCOPROTEIN; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

EID: 84929433114     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0477-7     Document Type: Letter
Times cited : (13)

References (5)
  • 1
    • 84875393191 scopus 로고    scopus 로고
    • Ineffectiveness of crizotinib on brain metastases in two cases of lung adenocarcinoma with EML4-ALK rearrangement
    • PID: 23486270
    • Maillet D, Martel-Lafay I, Arpin D, et al. Ineffectiveness of crizotinib on brain metastases in two cases of lung adenocarcinoma with EML4-ALK rearrangement. J Thorac Oncol. 2013;8:e30–1.
    • (2013) J Thorac Oncol , vol.8 , pp. 30-31
    • Maillet, D.1    Martel-Lafay, I.2    Arpin, D.3
  • 2
    • 79957487193 scopus 로고    scopus 로고
    • CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib
    • PID: 21422405
    • Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 2011;29:e443–5.
    • (2011) J Clin Oncol , vol.29 , pp. 443-445
    • Costa, D.B.1    Kobayashi, S.2    Pandya, S.S.3
  • 3
    • 84883390161 scopus 로고    scopus 로고
    • High-dose crizotinib for brain metastases refractory to standard-dose crizotinib
    • PID: 23945393
    • Kim YH, Ozasa H, Nagai H, et al. High-dose crizotinib for brain metastases refractory to standard-dose crizotinib. J Thorac Oncol. 2013;8:e85–6.
    • (2013) J Thorac Oncol , vol.8 , pp. 85-86
    • Kim, Y.H.1    Ozasa, H.2    Nagai, H.3
  • 4
    • 84919779490 scopus 로고    scopus 로고
    • Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases
    • COI: 1:CAS:528:DC%2BC2cXhsFeju7%2FK, PID: 25205428
    • Kodama T, Hasegawa M, Takanashi K, et al. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol. 2014;74:1023–8.
    • (2014) Cancer Chemother Pharmacol , vol.74 , pp. 1023-1028
    • Kodama, T.1    Hasegawa, M.2    Takanashi, K.3
  • 5
    • 84908569219 scopus 로고    scopus 로고
    • Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
    • COI: 1:CAS:528:DC%2BC2cXhsVSmt77K, PID: 25153538
    • Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol. 2014;15:1119–28.
    • (2014) Lancet Oncol , vol.15 , pp. 1119-1128
    • Gadgeel, S.M.1    Gandhi, L.2    Riely, G.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.